ARS Pharmaceuticals, Inc.
SPRY
$8.54
$0.526.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 184.47% | -67.56% | 1,471.62% | 3,043.40% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 184.47% | -67.56% | 1,471.62% | 3,043.40% | -- |
| Cost of Revenue | 162.53% | 146.58% | 141.28% | 30.79% | -22.70% |
| Gross Profit | 207.08% | -77.64% | 973.90% | 204.72% | 175.03% |
| SG&A Expenses | 75.66% | 68.93% | 287.69% | 507.25% | 416.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.45% | 76.60% | 259.81% | 299.82% | 242.25% |
| Operating Income | -61.78% | -187.86% | -144.58% | -210.39% | -181.81% |
| Income Before Tax | -78.60% | -182.44% | -167.41% | -258.60% | -229.77% |
| Income Tax Expenses | -- | -127.78% | -- | -- | -- |
| Earnings from Continuing Operations | -78.60% | -182.76% | -167.41% | -258.60% | -229.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.60% | -182.76% | -167.41% | -258.60% | -229.77% |
| EBIT | -61.78% | -187.86% | -144.58% | -210.39% | -181.81% |
| EBITDA | -61.93% | -186.92% | -143.02% | -208.93% | -179.93% |
| EPS Basic | -76.39% | -181.39% | -162.66% | -252.90% | -224.37% |
| Normalized Basic EPS | -76.38% | -164.86% | -162.66% | -252.97% | -172.08% |
| EPS Diluted | -76.39% | -199.74% | -162.66% | -252.90% | -224.37% |
| Normalized Diluted EPS | -76.38% | -179.40% | -162.66% | -252.97% | -172.08% |
| Average Basic Shares Outstanding | 1.26% | 1.67% | 1.83% | 1.58% | 1.63% |
| Average Diluted Shares Outstanding | 1.26% | -16.93% | 1.83% | 1.58% | 1.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |